Rigosertib sodium is under clinical development by Traws Pharma and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rigosertib sodium LoA Report. Buy the report here.

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rigosertib sodium overview

Rigosertib (Estybon, ON 01910.Na and SyB L-1101) is under development for the treatment of metastatic kirsten rat sarcoma positive (KRAS+) lung adenocarcinoma, higher-risk myelodysplastic syndromes (MDS), recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma, chronic myelomonocytic leukemia (CMML), neuroblastoma, metastatic melanoma, rhabdomyosarcoma ,non small cell lung cancer and various RASopathies (unspecified). It is a administered orally and intravenously. It acts by targeting phosphoinositide 3-kinase (PI3K) and polo-like kinase (PLK).
It was also under development for the treatment of metastatic pancreatic cancer, ovarian cancer, mantle cell lymphoma, refractory/relapsed multiple myeloma, refractory/relapsed chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia and hairy cell leukemia. It was also under development for acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myeloproliferative neoplasms including myelofibrosis, essential thrombocythemia, Polycythemia Vera, Juvenile Myelomonocytic Leukemia (JMML), Coronavirus Disease 2019 (COVID-19), Renal Cell Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Esophageal Squamous Cell Carcinoma (ESCC), skin squamous cancer,  colorectal cancer, cervical squamous cell cancer, penile squamous cell cancer and anal squamous cell cancer.

Traws Pharma overview

Onconova Therapeutics (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib and ON123300. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting the medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partnered with biopharmaceutical companies and medical organizations in the US. Onconova is headquartered in Newtown, Pennsylvania, the US.

For a complete picture of Rigosertib sodium’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.